Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022968 | 0.77 | POLB (0.55) | MAPTMAPK1KMT2AMEN1POLB | |
| SCHEMBL4910981 | 0.71 | ALDH1A1 (0.52) | MAPTMAPK1KMT2AMEN1POLB | |
| SCHEMBL17195555 | 0.71 | HDAC6 (0.57) | MAPTKMT2AMEN1POLBTP53 | |
| SCHEMBL17038755 | 0.70 | POLB (0.52) | MAPTMAPK1KMT2AMEN1POLB | |
| SCHEMBL17039017 | 0.70 | MEN1 (0.52) | MAPTKMT2AMEN1POLBTP53 | |
| SCHEMBL17038739 | 0.69 | POLB (0.51) | MAPTMAPK1KMT2AMEN1POLB | |
| SCHEMBL17199375 | 0.69 | POLB (0.51) | MAPTKMT2AMEN1POLBTP53 | |
| SCHEMBL21036099 | 0.69 | POLB (0.48) | MAPTMAPK1KMT2AMEN1POLB | |
| SCHEMBL30497877 | 0.69 | POLB (0.78) | MAPTMAPK1POLBTP53ALDH1A1 | |
| SCHEMBL30589593 | 0.68 | PTGS1 (0.66) | MAPTMAPK1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931063-B3 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ZIOPHARM ONCOLOGY INC (US) | 2009-04-08 | — | — | EP | claimed |
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | claimed |
| US-6919344-B2 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | ASTA MEDICA, AKTIENGESELLSCHAFT (DE) | 2005-07-19 | — | — | US | claimed |
| US-20030207892-A1 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | BAXTER HEALTHCARE S.A. (CH) | 2003-11-06 | — | — | US | claimed |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | ZIOPHARM ONCOLOGY, INC. | 2002-10-31 | — | — | US | claimed |
| US-6344467-B1 | ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSANT/IMMUNOMODULATING PROPERTIES | ASTA MEDICA AG (DE) | 2002-02-05 | — | — | US | claimed |
| EP-0931063-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA Medica Aktiengesellschaft (DE) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009946-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-03-12 | — | — | WO | claimed |
| EP-0931063-B3 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ZIOPHARM ONCOLOGY INC (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ASTA MEDICA AKTIENGESELLSCHAFT | 2008-01-31 | — | — | US | disclosed |
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | disclosed |
| EP-1071420-B1 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY | BAXTER HEALTHCARE SA (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-6919344-B2 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | ASTA MEDICA, AKTIENGESELLSCHAFT (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20030023093-A1 | United states patent office | ASTA MEDICA AKTIENGESELLSCHAFT | 2003-01-30 | — | — | US | disclosed |
| US-6232327-B1 | AND PHYSIOLOGICALLY TOLERABLE ACID ADDITION SALTS, N-OXIDES | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-05-15 | — | — | US | disclosed |
| EP-1071420-A1 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY | ASTA Medica Aktiengesellschaft (DE) | 2001-01-31 | — | — | EP | disclosed |
| US-6008231-A | ANTIALLERGENS, ANTIHISTAMINES, IMMUNOSUPPRESSANTS, IMMUNOMODULATORS | ASTA MEDICA AKTIENGESELLSCHGT (DE) | 1999-12-28 | — | — | US | disclosed |
| WO-1999051224-A1 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-10-14 | — | — | WO | disclosed |
| EP-0931063-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA Medica Aktiengesellschaft (DE) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009946-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023093-A1 | United states patent office | IDO1, IDO2, TDO2 | MAPT 3529/4885MAPK1 3834/4885KMT2A 3506/4885 |
| US-20030207892-A1 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | MAPT 3185/4885MAPK1 4718/4885KMT2A 1454/4885 |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | IDO1, IDO2, TDO2 | MAPT 3557/4885MAPK1 4016/4885KMT2A 3037/4885 |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | MAPT 3626/4885MAPK1 4741/4885KMT2A 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.